Camp4 Therapeutics vs DBV Technologies
DBV Technologies is the larger business, with $5.6m of revenue in fiscal 2025 against $3.5m for Camp4 Therapeutics (1.6 times as much). Camp4 Therapeutics grew faster (436.5% against 35.8%). Camp4 Therapeutics kept more of each dollar of sales as profit: a net margin of -2298.5% against -2607.3%. Camp4 Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Camp4 TherapeuticsCAMP, 2025 | DBV TechnologiesDBVT, 2025 |
|---|---|---|
| Revenue | $3.5m | $5.6m |
| Revenue growth | 436.5% | 35.8% |
| Net income | −$80.4m | −$147m |
| Operating margin | -1502.4% | -2609.2% |
| Net margin | -2298.5% | -2607.3% |
| Return on equity | -145.1% | -149.8% |
| Free cash flow | −$29.8m | −$122m |
| Cash | $110m | $194m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 48 | 125 |
| Market value | $196m | $4.08bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 5 buys, 6 sales | 0 buys, 7 sales |